Jane Street’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,280
Closed -$253K 8544
2020
Q3
$253K Sell
2,280
-4,246
-65% -$456K ﹤0.01% 6126
2020
Q2
$667K Buy
+6,526
New +$698K ﹤0.01% 4645
2019
Q4
Sell
-5,679
Closed -$650K 6187
2019
Q3
$650K Buy
5,679
+576
+11% +$57.3K ﹤0.01% 3183
2019
Q2
$486K Buy
+5,103
New +$481K ﹤0.01% 3614
2018
Q4
Sell
-3,841
Closed -$307K 6266
2018
Q3
$307K Sell
3,841
-804
-17% -$74.9K ﹤0.01% 4192
2018
Q2
$461K Buy
+4,645
New +$401K ﹤0.01% 3664
2017
Q1
Sell
-5,994
Closed -$644K 5038
2016
Q4
$644K Sell
5,994
-18,752
-76% -$2.19M ﹤0.01% 2570
2016
Q3
$3.08M Buy
+24,746
New +$2.92M 0.01% 851
2016
Q2
Sell
-3,217
Closed -$374K 4918
2016
Q1
$368K Buy
3,217
+299
+10% +$35.1K ﹤0.01% 2967
2015
Q4
$416K Sell
2,918
-271
-8% -$31.3K ﹤0.01% 2699
2015
Q3
$286K Buy
3,189
+1,312
+70% +$138K ﹤0.01% 2839
2015
Q2
$216K Sell
1,877
-1,063
-36% -$112K ﹤0.01% 3192
2015
Q1
$281K Buy
+2,940
New +$220K ﹤0.01% 2577
2014
Q3
Sell
-11,720
Closed -$521K 3374
2014
Q2
$521K Buy
+11,720
New +$479K 0.01% 1374

Other funds holding CBPO

Jane Street's CBPO Position: Q4 2020 in Review

Jane Street sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2020, closing a stake of 2,280 shares — an estimated $253K sold.

Jane Street first reported a position in CBPO in Q2 2014 and held it in 14 quarters. The position peaked at $3.08M in Q3 2016. 89 funds tracked by Wall St. Rank hold CBPO as of Q4 2020.

  • Jane Street reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2020 after selling out during the quarter.
  • Jane Street sold 2,280 China Biologic Products Holdings, Inc. shares in Q4 2020, an estimated $253K.
  • Jane Street first reported a position in China Biologic Products Holdings, Inc. in Q2 2014 and held it in 14 quarters.
  • Jane Street's China Biologic Products Holdings, Inc. position peaked at $3.08M in Q3 2016.
  • 89 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2020.

Based on Jane Street's 13F filing for Q4 2020, filed 17 Feb 2021.